SCHEMBL3026469

SCHEMBL3026469

CC(=O)OCC(OC(C)=O)C(=O)Nc1c(I)c(C(N)=O)c(I)c(C(=O)Cl)c1I

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.30
MAPK1 P28482 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3026646 0.95 LMNA (0.36) LMNAPOLBMAPK1TDP1
SCHEMBL9318639 0.89 LMNA (0.38) LMNA
SCHEMBL6228292 0.86 LMNA (0.33) LMNA
SCHEMBL3024742 0.86 POLB (0.40) LMNAPOLBMAPK1TDP1
SCHEMBL3023741 0.85 LMNA (0.32) LMNA
SCHEMBL9237721 0.84 LMNA (0.36) LMNA
SCHEMBL3020429 0.83 LMNA (0.46) LMNA
SCHEMBL709956 0.83 LMNA (0.33) LMNA
SCHEMBL3016225 0.81 LMNA (0.40) LMNA
SCHEMBL709410 0.81 LMNA (0.33) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100189656-A1 CONTRAST AGENTS GE HEALTHCARE AS (NO) 2010-07-29 US disclosed
US-20100189656-A1 CONTRAST AGENTS GE HEALTHCARE AS (NO) 2010-07-29 US disclosed
US-20100189656-A1 CONTRAST AGENTS GE HEALTHCARE AS (NO) 2010-07-29 US disclosed
WO-2009005364-A1 CONTRAST AGENTS GE HEALTHCARE AS (NO) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100189656-A1 CONTRAST AGENTS IPO4, TPO, IPO11 LMNA 1835/4885POLB 2343/4885MAPK1 2071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.